Alan B. Astrow, M.D.

Massimo Cristofanilli, MD, is an accomplished board-certified medical oncologist with more than two decades of experience as physician, investigator, researcher and leader. He has demonstrated original and innovative vision in the field of molecular diagnostics, liquid biopsy, translational research and drug development. Additionally, Dr. Cristofanilli has an extensive background in clinical trial design and is a key thought leader in the field of metastatic and locally advanced breast cancer.At Weill Cornell Medicine and NewYork-Presbyterian, Dr. Cristofanilli serves as the Director of Breast Medical Oncology, the Associate Director of Precision Oncology at the Meyer Cancer Center (MCC), and the co-leader of the MCC Breast Cancer Disease Management Team, as well as the Scientific Director of the Englander Institute of Precision Medicine (EIPM).Dr. Cristofanilli received his medical degree from the University "La Sapienza" in Rome with Honors where he subsequently completed his fellowship in medical oncology. He completed an Internal Medicine residency at Cabrini Medical Center in New York and a medical oncology fellowship at The University of Texas MD Anderson Cancer Center, where he also served as Faculty in the Department of Breast Medical Oncology for more than a decade.Dr. Cristofanilli has held several leadership positions over the years, including Chair of Medical Oncology and Associate Director of Clinical Research at the Fox Chase Cancer Center and Associate Director of Translational Research at Thomas Jefferson University. From 2015-2021, Dr. Cristofanilli was Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago where he also served as the Director of the Breast Disease Team, Director of the Robert Lurie Cancer Center OncoSET Precision Medicine Program, and Associate Director of Clinical Research.In addition to his clinical expertise, Dr. Cristofanilli's research focuses on biomarkers of endocrine resistance in breast cancer, liquid biopsies and novel drug development. His research in the areas of novel drug development, circulating tumor cells (CTCs) and ctDNA have led to improved treatments for breast cancer. Dr. Cristofanilli is an internationally recognized expert in the research and treatment of Inflammatory Breast Cancer (IBC), the most aggressive and deadly form of breast cancer. He is the founder and President of the IBC International Consortium (IBC-IC). Additionally, Dr. Cristofanilli is globally recognized for his contributions on the detection of micrometastatic disease in breast cancer and a key opinion leader in drug development in hormone-receptor positive metastatic breast cancer. He has co-authored more than 400 peer-reviewed manuscripts.

Drew Gunio, MD is a radiologist specializing in Musculoskeletal Imaging. He is an Assistant Professor of Clinical Radiology at Weill Cornell Medicine and an Assistant Attending Radiologist at the NewYork-Presbyterian/Weill Cornell Medical Center.Dr. Gunio graduated from the University of Georgia where he earned his B.S. in Biology in 2008. He then received his M.S. in Human Genetics in 2009 from Tulane University. In 2010 Dr. Gunio received his M.D. from the Medical College of Georgia.Following preliminary residency at Icahn SOM at Mount Sinai Beth Israel, Dr. Gunio completed his residency in Diagnostic Radiology from 2016 to 2020 at Icahn SOM at Mount Sinai West. He then completed his fellowship in Musculoskeletal Imaging from 2020 to 2021 at University of Pennsylvania. Dr. Gunio joined the faculty at Weill Cornell Medicine in July 2021 as an AssistantProfessor of Clinical Radiology.Dr. Gunio is a member of the following radiological societies:• American Roentgen Ray Society• American College of Radiology• Society of Skeletal Imaging• Radiological Society of North America

Dr. Ferrarone graduated medical school from New York Medical College. He completed both his residency in internal medicine and his fellowship in medical oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. After his fellowship, Dr. Ferrarone received training in cancer biology research under the guidance of the Nobel laureate Dr. Harold Varmus. Dr. Ferrarone’s clinical and research efforts are focused on lung cancer. In his laboratory, he studies how mutations in certain genes influence the growth of tumors and their interaction with the immune system. The aim of his research is to provide new insights into the behavior of lung cancer, to enable the development of new cancer treatments and the rational design of clinical trials.